Stroke Prevention in Nigeria 2 Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

Also called NCT06526117

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06526117
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Nigeria (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06526117. Allocation not applicable; no masking; primary purpose prevention. Start 2024-08-05 (actual); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Stroke Prevention in Nigeria 2 Trial
Acronym
SPRING-2
Condition
Sickle Cell Disease
Condition
Stroke
Intervention (Drug)
Hydroxyurea
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
Aminu Kano Teaching Hospital (class: other)
Collaborator
Murtala Muhammed Specialist Hospital (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct06526117
Content hash
d01e7d62458977241a686ea227c57526297f1dcb3d97c1884975aa38365f7268